User profiles for D. Flockhart

Flockhart D

Professor of Medicine, Indiana University School of Medicine
Verified email at iupui.edu
Cited by 30924

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

Z Desta, X Zhao, JG Shin, DA Flockhart - Clinical pharmacokinetics, 2002 - Springer
Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large differences in
the pharmacokinetics of a number of clinically important drugs. On the basis of their ability to …

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges

…, DW Lin, DM Roden, PB Watkins, D Flockhart… - Nature reviews Drug …, 2007 - nature.com
Serious adverse drug reactions (SADRs) are a major cause of morbidity and mortality
worldwide. Some SADRs may be predictable, based upon a drug's pharmacodynamic and …

The pharmacogenetics research network: from SNP discovery to clinical drug response

…, NL Benowitz, ME Dolan, DA Flockhart… - Clinical …, 2007 - Wiley Online Library
The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators
with a wide range of research interests, but all attempting to correlate drug response with …

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

…, DF Hayes, Z Desta, DA Flockhart - Journal of the …, 2003 - academic.oup.com
Background: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen
and other active metabolites by cytochrome P450 (CYP) enzymes. …

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

…, JM Rae, DF Hayes, DA Flockhart - Journal of the …, 2005 - academic.oup.com
D. Hayes has received honoraria and research funding from Astra Zeneca and research …
Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and …

[HTML][HTML] Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

…, FJ Couch, WL Lingle, DA Flockhart… - Journal of Clinical …, 2005 - nlp.case.edu
… to 40 mg/d) with 20 mg/d. Furthermore, lower doses of tamoxifen (1 mg/d and 5 mg/d) have
similar effects on biologic markers of proliferation when compared with 20 mg/d, 23 but have …

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a …

…, JC Gorski, DR Jones, SD Hall, DA Flockhart… - … of Pharmacology and …, 2003 - ASPET
We used human liver microsomes (HLMs) and recombinant cytochromes P450 (P450s) to
identify the routes of efavirenz metabolism and the P450s involved. In HLMs, efavirenz …

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6

…, BA Ward, NV Soukhova, DA Flockhart - Journal of Pharmacology …, 2004 - ASPET
We performed comprehensive kinetic, inhibition, and correlation analyses in human liver
microsomes and experiments in expressed human cytochromes P450 (P450s) to identify …

[HTML][HTML] Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel …

…, S Badve, A Thor, DA Flockhart… - Journal of Clinical …, 2008 - ncbi.nlm.nih.gov
Purpose No biomarkers have been identified to predict outcome with the use of an
antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has …

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

…, AM Nibbe, Z Desta, A Nguyen, DA Flockhart… - Breast cancer research …, 2007 - Springer
Background Tamoxifen is biotransformed to the potent anti-estrogen, endoxifen, by the
cytochrome P450 (CYP) 2D6 enzyme. CYP2D6 genetic variation and inhibitors of the enzyme …